You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 302 No. 3, July 15, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Neurogenetics
 •Oncology
 •Brain Cancer
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Genetic Disorders
 •Genetics, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

One Step Forward Toward Identification of the Genetic Signature of Glioblastomas

Boris Pasche, MD, PhD; Richard M. Myers, PhD

JAMA. 2009;302(3):325-326.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cancer is a disease of the genome at the level of gene expression, epigenetic modifications such as DNA methylation, and DNA alterations. For more than 3 decades, many lines of research have shown that acquisition of genetic changes is a major and required step in the development of most cancers. First, ionizing radiation and chemicals that damage DNA and cause mutations also cause cancer.1 Second, genomic alterations such as translocations that result in the production of a specific gene fusion product are associated with some types of cancer. Such is the case for the translocations between chromosomes 9 and 22 in chronic myeloid leukemia and the translocation between chromosomes 15 and 17 in acute promyelocytic leukemia.2 Third, the introduction of genomic DNA from human cancer cells into normal cells can render the normal cells cancerous.3

In the past 2 decades, many genomic . . . [Full Text of this Article]

Author Affiliations: Division of Hematology/Oncology, University of Alabama at Birmingham, and UAB Comprehensive Cancer Center, Birmingham (Dr Pasche); and HudsonAlpha Institute for Biotechnology, Huntsville, Alabama (Mr Myers). Dr Pasche is also Contributing Editor, JAMA.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

A Network Model of a Cooperative Genetic Landscape in Brain Tumors
Markus Bredel, Denise M. Scholtens, Griffith R. Harsh, Claudia Bredel, James P. Chandler, Jaclyn J. Renfrow, Ajay K. Yadav, Hannes Vogel, Adrienne C. Scheck, Robert Tibshirani, and Branimir I. Sikic
JAMA. 2009;302(3):261-275.
ABSTRACT | FULL TEXT  

Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas
Ajay K. Yadav, Jaclyn J. Renfrow, Denise M. Scholtens, Hehuang Xie, George E. Duran, Claudia Bredel, Hannes Vogel, James P. Chandler, Arnab Chakravarti, Pierre A. Robe, Sunit Das, Adrienne C. Scheck, John A. Kessler, Marcelo B. Soares, Branimir I. Sikic, Griffith R. Harsh, and Markus Bredel
JAMA. 2009;302(3):276-289.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.